Crunching the Abbott Spinoff Numbers (ABT, ABBV) : Small Cap Diligence SmallCap Network Daclizumab, bardoxolone (chronic kidney disease), and elotuzumab (multiple myeloma) are all in Phase III trials, with about ten more solid developments in Phase II testing. As for Abbott Laboratories, the device and equipment manufacturer, it's also a ... |
